Neuronal substrate of the saccadic inhibition deficit in schizophrenia investigated with 3-dimensional event-related functional magnetic resonance imaging

Archives of General Psychiatry
Mathijs RaemaekersNick F Ramsey

Abstract

Several studies have shown that the ability to suppress automatic saccadic eye movements is impaired in patients with schizophrenia as well as in their first-degree relatives, and suggest that this impairment is a potential vulnerability marker for schizophrenia. The neurobiological mechanisms underlying normal saccade production and inhibition, revealed in primate studies, indicate that the impairment may result from a failure of the oculomotor system to effectively exert inhibitory control over brainstem structures. Functional localization of the affected brain structure(s) potentially provides a physiological measure for the investigation of vulnerability markers in schizophrenia. The hemodynamic response to discrete visual stimuli was measured during prosaccades (saccades toward a peripheral stimulus), antisaccades (saccades toward a position opposite to a peripheral stimulus), and active fixation (holding fixation and ignoring a peripheral stimulus) in 16 patients with schizophrenia receiving atypical neuroleptics and 17 healthy control subjects using an event-related functional magnetic resonance imaging task design. Brain responses were detected in the frontal and parietal regions of the oculomotor system in all 3 tasks....Continue Reading

Citations

Jul 21, 2004·Current Psychiatry Reports·Vaibhav A DiwadkarMatcheri S Keshavan
Dec 1, 2006·Schizophrenia Bulletin·Bruce I TuretskyNeal R Swerdlow
Jun 15, 2007·Schizophrenia Bulletin·Hernàn PicardMarie-Odile Krebs
Aug 31, 2007·Cerebral Cortex·Ulrich EttingerSteven C R Williams
Feb 1, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Ulrich EttingerSteven C R Williams
Jun 14, 2006·Journal of Cognitive Neuroscience·M RaemaekersN F Ramsey
Jan 12, 2007·Journal of Cognitive Neuroscience·Junichi ChikazoeYasushi Miyashita
Dec 7, 2007·Experimental Brain Research·Jason J S BartonDara S Manoach
Jun 12, 2010·Schizophrenia Bulletin·Ulrich EttingerMarco Picchioni
Apr 27, 2005·NeuroImage·Matthijs VinkNick F Ramsey
Dec 5, 2014·European Archives of Psychiatry and Clinical Neuroscience·Stefan DowiaschFrank Bremmer
Feb 6, 2013·Biological Psychiatry·Dara S ManoachJason J S Barton
Dec 26, 2012·Schizophrenia Research·J GigauxS Richard-Devantoy
Oct 28, 2008·Brain and Cognition·Diane C Gooding, Michele A Basso
Oct 7, 2008·Brain and Cognition·Jennifer E McDowellBrett A Clementz
Dec 4, 2008·Applied & Preventive Psychology : Journal of the American Association of Applied and Preventive Psychology·Daniel G Dillon, Diego A Pizzagalli
Aug 19, 2007·Biological Psychology·Cosima FrankeNorbert Kathmann
Apr 27, 2005·Human Brain Mapping·Matthijs VinkNick F Ramsey
Jun 2, 2005·The European Journal of Neuroscience·S F W NeggersN F Ramsey
Apr 2, 2009·Psychiatry and Clinical Neurosciences·Mai Fukumoto-MotoshitaTetsuya Matsuda
Feb 10, 2007·Human Brain Mapping·Martina T MitterschiffthalerSteven C R Williams
Jun 30, 2006·Psychophysiology·Samuel B Hutton, Ulrich Ettinger
Jun 8, 2011·The European Journal of Neuroscience·Masayuki Watanabe, Douglas P Munoz
Feb 18, 2011·American Journal of Primatology·Kerrie Lewis Graham
Nov 19, 2011·Psychophysiology·Désirée S AichertUlrich Ettinger
May 4, 2005·Biological Psychiatry·Christoph J PlonerCharles Pierrot-Deseilligny
Apr 11, 2006·Biological Psychiatry·Matthijs VinkRené S Kahn
Nov 4, 2004·Biological Psychiatry·Manjinder S BagaryMaria A Ron
Feb 12, 2005·Biological Psychiatry·Carine CondyBertrand Gaymard
Sep 17, 2005·Biological Psychiatry·Mathijs RaemaekersRene S Kahn

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here